Sagimet Biosciences Inc (SGMT) concluded trading on Thursday at a closing price of $8.61, with 9.07 million shares of worth about $78.06 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 70.50% during that period and on June 12, 2025 the price saw a gain of about 39.10%. Currently the company’s common shares owned by public are about 30.67M shares, out of which, 23.62M shares are available for trading.
Stock saw a price change of 80.13% in past 5 days and over the past one month there was a price change of 170.75%. Year-to-date (YTD), SGMT shares are showing a performance of 91.33% which increased to 76.43% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.73 but also hit the highest price of $7.38 during that period. The average intraday trading volume for Sagimet Biosciences Inc shares is 1.03 million. The stock is currently trading 102.85% above its 20-day simple moving average (SMA20), while that difference is up 154.18% for SMA50 and it goes to 108.65% higher than SMA200.
Sagimet Biosciences Inc (NASDAQ: SGMT) currently have 30.67M outstanding shares and institutions hold larger chunk of about 36.23% of that.
The stock has a current market capitalization of $264.11M and its 3Y-monthly beta is at 2.38. It has posted earnings per share of -$1.78 in the same period. It has Quick Ratio of 20.26 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for SGMT, volatility over the week remained 15.95% while standing at 8.99% over the month.
Stock’s fiscal year EPS is expected to drop by -74.49% while it is estimated to decrease by -21.88% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Oppenheimer on December 06, 2024 offering an Outperform rating for the stock and assigned a target price of $30 to it. Coverage by UBS stated Sagimet Biosciences Inc (SGMT) stock as a Buy in their note to investors on November 12, 2024, suggesting a price target of $12 for the stock. On June 28, 2024, Goldman Downgrade their recommendations, while on May 02, 2024, H.C. Wainwright Initiated their ratings for the stock with a price target of $32. Stock get an Outperform rating from Leerink Partners on March 25, 2024.
